Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Genstruct signs partnership agreement with Gene Logic
As part of this collaboration, Gene Logic will provide its toxicology databases and data on specific compounds obtained by the company’s gene expression technology for preclinical and clinical
As part of this collaboration, Gene Logic will provide its toxicology databases and data on specific compounds obtained by the company’s gene expression technology for preclinical and clinical
Seroquel extended-release (XR) tablet is also now available in two new strengths, 50mg and 150mg. Once-daily Seroquel XR is the only FDA-approved medication for the treatment of acute
Fourth-quarter reported revenues were $448.0 million, down 2.6% compared to $459.7 million reported for the fourth quarter of 2007. On a currency-neutral basis, quarterly revenues increased 3.0% compared
Benvenue Medical said that initial clinical cases in Europe using the Kiva system have been successfully performed. The company added that it is preparing for the commercial launch
For the fourth quarter, total revenue from continuing operations increased 6% to a record $37.1 million compared to $34.9 million for the fourth quarter of 2007. RA sales
According to the company, geneX is a synthetic bone graft material with a unique bi-phasic composition manufactured through a proprietary process that confers the product with a reproducible
According to CytoCore, the SoftPAP cervical cell collector offers quicker, more accurate specimen collection with minimal possibility of user error. It is designed to consistently sample the entire
According to Etex, Beta-bsm and Gamma-bsm are next generation bone substitute materials based on the company’s nanocrystalline calcium phosphate technology. This hard-setting nanocrystalline technology provides the optimal osteoconductive
Under the agreement, GTC will establish the appropriate cell lines and demonstrate production over the next 12 months. JCOM has the option for exclusive marketing rights in Asia.
The Phase I study will evaluate the safety, tolerability and pharmacokinetic profile of GTx-758 using a single ascending dose, double-blind, placebo-controlled design in healthy male volunteers. Preclinical in